Days ahead of Amgen split, Cytokinetics reads out post-hoc data suggesting heart drug works better in sicker patients — but can the CEO win over skeptics?

While Cytokinetics’ heart drug technically met its primary endpoint back in November, it missed a key secondary endpoint — reduction in cardiovascular death — which eventually cost the company two partnerships. Now the team is back with data suggesting the drug works better in sicker patients, and it’s planning...

Click to view original post